石四藥(02005.HK)研分拆江蘇博生A股上市
石四藥集團(02005.HK)公佈,正考慮可能將江蘇博生的股份分拆並於中國內地的證券交易所獨立掛牌及或上市。江蘇博生爲間接全資附屬,主要從事製造及銷售藥品及醫用材料。
集團指,可能分拆上市正處於初步階段,實行須視乎市場狀況及相關監管機構的批準而定。於公告日期(18日),尚未有就可能分拆上市向聯交所有提交的申請,亦尚未有就可能分拆上市向中國內地的證券交易所提交的上市或掛牌申請,亦尚未有關於是否及何時進行可能分拆上市的最終決定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.